DCN: 16-001173 v.2.1

BISPECTRA

100 Majestic Way, Bangor, PA 18013 / www.biospectra.us

Effective Date:	16-May-2017	16-May-2020	: Date of Next Review
Prepared By:	Jamie Storm	16-001173 v.2.0	: Supersedes
QA/QC Approval:	Nicole Fisher	Dora Meissner	: Management Approval
Reason for Revision:	See Revision History in ensur		

MES MONOHYDRATE

CERTIFICATE OF ANALYSIS

BIO EXCIPIENT GRADE / ME3220-K025

LOT: ME3220-009-1217

Manufacturing Date: 10/16/2017

Retest Date: 10/31/2019

Manufacturing Site: 100 Majestic Way, Bangor PA, 18013 Packaging Date: 12/19/2017

Packaging Site: 100 Majestic Way, Bangor PA, 18013

Analysis		SPECIFICATION	TEST RESULT	
Absorbance	260 nm	0.1000 a.u. max.	0. 0071 a.u.	
Ausordance	280 nm	0.1000 a.u. max.	0. 0048 a.u.	
Appearance and Color		White / Crystals	White / Crystals	
Assay		99.0% min.	99.72%	
Chloride		0.005% max.	<0.005%	
Color (1M, Alkaline)		Colorless	Colorless	
	DNase	None Detected	None Detected	
Enzymes	RNase	None Detected	None Detected	
	Protease	None Detected	None Detected	
Heavy Metals		2 ppm max.	< 2 ppm	
Identification (IR)		Passes Test	Passes Test	
pH (5% Soln.)		3.1 - 3.5	3.34 @ 21.5 °C	
pH (5M)		2.5 - 4.5	3.18 @ 22.3 °C	
pK_a		5.9 - 6.3	6.0	
Residue on Ignition		0.05% max.	<0.0150%	
Solubility		Passes Test	Passes Test	
Sulfate		0.005% max.	<0.005%	
	Arsenic (As)	5 ppm max.	< 5 ppm	
Trace Elements	Copper (Cu)	5 ppm max.	< 5 ppm	
Trace Elements	Iron (Fe)	5 ppm max.	< 5 ppm	
	Lead (Pb)	5 ppm max.	< 5 ppm	

COUNTRY OF ORIGIN: U.S.A.

TEST METHOD REFERENCE: DCN: 16-001016

DCN: 16-001173 v.2.1

<u>INTENDED USE:</u> Material represented by this Certificate of Analysis is suitable to be used only as the following: ICH Q7 Compliant cGMP Manufactured Excipient for use in further Manufacturing. The material represented by this Certificate of Analysis is not suitable to be used as an Active Pharmaceutical Ingredient, Drug Product or Household Item.

OVI STATEMENT: Based on the manufacturing process and the controlled handling and storage of this product, there is no potential for any of the residual solvents listed in the current USP method <467> Tables 1, 2, 3, or 4 to be present at the specified limits; furthermore, if tested this product would comply with USP/NF requirements.

Prepared by: H. Beum	_ Date:	1/2/18
Reviewed by: Cayout at	_ Date:	112/18